#atherosclerosis

• Anti-sclerotic — Preventing, combating, delaying, or treating sclerosis; a pharmaceutical preparation, chemical compound, or therapeutic regimen designed to prevent the pathological stiffening, hardening, or thickening of connective tissues or arterial walls (arteriosclerosis). It acts locally or systemically by regulating lipid metabolism, reducing vascular inflammation, and protecting the elasticity of cellular structures.
• Arteriopathy — A generic name attributed to any disease or organic or functional pathological condition of the arteries, regardless of its etiology (inflammatory, degenerative, or metabolic). In daily clinical practice, the term most frequently refers to peripheral artery disease of the lower limbs, a chronic obstructive condition caused by atherosclerosis that progressively reduces the arterial lumen and peripheral blood flow, causing intense pain during walking (intermittent claudication) and a risk of tissue ischemia.
• Atheroma — A pathological plaque or deposit composed of lipid substances (especially cholesterol), foam cells, cellular debris, and fibrous tissue that gradually accumulates within the intima tunic of large and medium arteries. Its development leads to the narrowing of the vascular lumen, reduction of arterial elasticity, and disruption of blood flow, representing the fundamental lesion of atherosclerosis.
• Atherosclerosis — A chronic and progressive cardiovascular disease characterized by the deposition of lipid substances (cholesterol) and calcium salts within the inner tunic of large and medium arteries, associated with connective tissue proliferation and vascular wall stiffening. This process gradually leads to the narrowing of the arterial lumen, reduced blood supply to organs, and represents the primary cause of myocardial infarction and stroke.